PFM
ALNY icon

Privium Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Privium Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Sell
11,372
-850
-7% -$256K 0.63% 27
2026
Q1 		$4.04M Buy
+12,222
New +$4.16M 0.84% 26
2025
Q2 		– Sell
-5,716
Closed -$1.54M – 57
2025
Q1 		$1.54M Buy
+5,716
New +$1.47M 0.4% 27
2024
Q3 		– Sell
-19,393
Closed -$4.8M – 84
2024
Q2 		$4.8M Sell
19,393
-1,500
-7% -$237K 1.22% 24
2024
Q1 		$3.12M Sell
20,893
-800
-4% -$133K 0.83% 29
2023
Q4 		$4.23M Buy
21,693
+1,670
+8% +$284K 1.18% 25
2023
Q3 		$3.55M Buy
+20,023
New +$3.82M 1.05% 27
2022
Q4 		– Sell
-2,100
Closed -$440K – 154
2022
Q3 		$440K Sell
2,100
-8,400
-80% -$1.6M 0.16% 68
2022
Q2 		$1.53M Buy
10,500
+5,000
+91% +$709K 0.51% 36
2022
Q1 		$898K Buy
5,500
+3,100
+129% +$472K 0.2% 65
2021
Q4 		$410K Buy
+2,400
New +$446K 0.08% 80

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Privium Fund Management's ALNY Position: Q2 2026 in Review

Privium Fund Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 7% in Q2 2026, selling an estimated $256K and leaving 11,372 shares worth $3.42M. The position accounts for 0.63% of the portfolio, ranked #27.

Privium Fund Management first reported a position in ALNY in Q4 2021 and has held it in 11 quarters since. The position peaked at $4.8M in Q2 2024. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Privium Fund Management held 11,372 shares of Alnylam Pharmaceuticals worth $3.42M as of Q2 2026.
  • Privium Fund Management sold 850 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $256K.
  • Alnylam Pharmaceuticals made up 0.63% of Privium Fund Management's portfolio in Q2 2026, its #27 holding.
  • Privium Fund Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • Privium Fund Management's Alnylam Pharmaceuticals position peaked at $4.8M in Q2 2024.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.